Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab in Melanoma and Bladder Cancer
NCT02553642Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2015
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in melanoma, bladder cancer, sponsored by Memorial Sloan Kettering Cancer Center. Started Sep 2015; status: completed.
02
Drugs
03
Conditions
melanomabladder cancer
Beyond the preview
Go deeper on NCT02553642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02553642.